Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218432 · ClinicalTrials.gov registry record · NA
A Study of the TheraBionic P1 Device in Breast Cancer
A NA study of HER2-Negative Breast Cancer and Breast Cancer Stage II, sponsored by Barbara Ann Karmanos Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07218432: Recruiting NA study of HER2-Negative Breast Cancer and Breast Cancer Stage II, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT07218432 is a NA study of HER2-Negative Breast Cancer and Breast Cancer Stage II that is actively recruiting participants, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 24 participants, below the 255-participant average among 49 other HER2-Negative Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07218432, a NA study of HER2-Negative Breast Cancer and Breast Cancer Stage II, is actively recruiting participants, sponsored by Barbara Ann Karmanos Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if adding cancer-specific amplitude-modulated radiofrequency electromagnetic field therapy (TheraBionic P1 device) to the treatment of resectable early-stage breast cancer will affect the pathological response.
Primary Outcome
Proportion of responders based on residual cancer cells in a resection specimen will be quantified. The response rate will be estimated as the proportion of patients who respond to treatment relative to all patients. The corresponding two-sided 95% confidence interval (CI) will be calculated using Clopper and Pearson's method
Conditions Studied
Interventions
- DEVICE TheraBionic P1 Device
Study Locations (1)
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-10 |
| Est. Completion | 2028-06-30 |
| Phase | NA |
What NCT07218432 shows while recruiting
NCT07218432 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 255-participant average among 49 other HER2-Negative Breast Cancer trials with a reported enrollment target (91% lower).
The record links to 5 conditions, with HER2-Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which TheraBionic P1 Device is the first listed.
NCT07218432 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07218432 about?
NCT07218432 is a clinical study titled "A Study of the TheraBionic P1 Device in Breast Cancer". The goal of this clinical trial is to learn if adding cancer-specific amplitude-modulated radiofrequency electromagnetic field therapy (TheraBionic P1 device) to the treatment of resectable early-stage breast cancer will affect the pathological response.
What is the current status of trial NCT07218432?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2026-10. Estimated completion is 2028-06-30.
What conditions does trial NCT07218432 study?
This clinical trial studies the following conditions: HER2-Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage I, Hormone Receptor Positive Tumor, Breast Cancer Stage IIIA.
What interventions are being tested in trial NCT07218432?
The interventions under investigation include: TheraBionic P1 Device (DEVICE).
Who is sponsoring clinical trial NCT07218432?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218432 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07218432's enrollment target sits among peer trials
24 39th of 49 higher than 10 of 49 other HER2-Negative Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HER2-Negative Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Breast Re-irradiation After Second Ipsilateral Lumpectomy
RECRUITING · NA
-
NearWave Optical Molecular Monitoring
RECRUITING · NA
-
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
RECRUITING · Phase 2
-
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia